“Trust is not something you can reclaim easily”: patenting in the field of direct-to-consumer genetic testing | Zendy

Sigrid Sterckx | Zendy; Julian Cockbain | Zendy; Heidi Howard | Zendy; Isabelle Huys | Zendy; Pascal Borry | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

“Trust is not something you can reclaim easily”: patenting in the field of direct-to-consumer genetic testing

Author(s) -

Sigrid Sterckx,

Julian Cockbain,

Heidi Howard,

Isabelle Huys,

Pascal Borry

Publication year - 2012

Publication title -

genetics in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.509

H-Index - 128

eISSN - 1530-0366

pISSN - 1098-3600

DOI - 10.1038/gim.2012.143

Subject(s) - field (mathematics) , genetic testing , business , microbiology and biotechnology , computer science , genetics , biology , mathematics , pure mathematics

Recently, 23andMe announced that it had obtained its first patent, related to "polymorphisms associated with Parkinson's disease" (US-B-8187811). This announcement immediately sparked controversy in the community of 23andMe users and research participants, especially with regard to issues of transparency and trust. The purpose of this article was to analyze the patent portfolio of this prominent direct-to-consumer genetic testing company and discuss the potential ethical implications of patenting in this field for public participation in Web-based genetic research.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research